摘要
目的研究丹参酮ⅡA磺酸钠(ST-IIA-S)对急性冠脉综合征(ACS)患者氧化应激水平的影响。方法入选惠州市第三人民医院重症医学科于2015年1月~12月ACS患者98例,随机分为STIIA-S组与对照组,每组各49例。对照组给予经皮冠状动脉介入(PCI)及抗血小板、β受体阻滞剂、硝酸酯类及他汀类等药物常规治疗,ST-IIA-S组给予常规治疗联合ST-IIA-S治疗。观察两组治疗前及治疗14 d后总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-9(MMP-9)、同型半胱氨酸(Hcy)、脂质过氧化物(LPO)、丙二醛(MDA)、超氧化物歧化酶(SOD)等指标、治疗有效率及不良反应。结果治疗14 d后两组患者TC、TG、HDL-C、LDL-C水平差异无统计学意义(P>0.05),治疗14 d后ST-IIA-S组hs-CRP、TNF-α、MMP-9、Hcy水平显著低于对照组(P<0.05),治疗14 d后ST-IIA-S组LPO、MDA水平显著低于对照组,SOD水平显著高于对照组(P均<0.05),ST-IIA-S组总有效率(91.84%)高于对照组总有效率(77.55%,P<0.05),治疗期内两组均无明显不良反应发生。结论 ST-IIA-S治疗ACS可有效改善患者炎性反应状态,降低氧化应激水平,临床疗效显著。
Objective To study the influence of sodium tanshinone ⅡA sulfonate (ST-ⅡA-S) on oxidative stress level in patients with acute coronary syndrome (ACS). Methods ACS patients (n=98) were chosen from the Intensive Care Unit of the Third People’s Hospital of Huizhou City from Jan. 2015 to Dec. 2015, and divided randomly into ST-ⅡA-S group and control group (each n=49). The control group was given percutaneous coronary intervention (PCI), anti-platelet therapy, β-receptor blocker, nitrates and statins, and ST-ⅡA-S group was given ST-ⅡA-S and the same therapies as control group. The indexes of total cholesterol (TC), triglyceride (TG), highdensity lipoprotein-cholesterol (HDL-C, low-density lipoprotein-cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), matrix metalloproteinase-9 (MMP-9), homocysteine (Hcy),lipid peroxide (LPO), malondialdehyde (MDA) and superoxide dismutase (SOD), and effective rate and adverse reactions were observed in 2 groups before and 14 d after treatment. Results The difference in levels of TC, TG,HDL-C and LDL-C had no statistical significance between 2 groups 14 d after treatment (P>0.05). The levels of hs-CRP, TNF-α, MMP-9 and Hcy were significantly lower in ST-IIA-S than those in control group (P<0.05).The levels of LPO and MDA were significantly lower, and SOD level was significantly higher in ST-IIA-S groupthan those in control group 14 d after treatment (all P<0.05). The total effective rate was 91.84% in ST-IIA-Sgroup and 77.55% in control group (P<0.05), and there were no significant adverse reactions observed in 2 groups during treatment period. Conclusion ST-IIA-S therapy can effectively relieve the inflammatory response, reduce oxidative stress level and has significant clinical efficacy in treatment of ACS.
作者
林传焕
刘毅君
谷欣
LIN Chuan-huan;LIU Yi-jun;GU Xin(Intensive Care Unit, Third People's Hospital of Huizhou City,Huizhou 516000, China)
出处
《中国循证心血管医学杂志》
2017年第1期63-65,70,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词
丹参酮ⅡA磺酸钠
急性冠脉综合征
炎性反应
氧化应激反应
Sodium tanshinone ⅡA sulfonate
Acute coronary syndrome
Inflammatory response
Oxidative stress reaction
